Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais

Abstract Introduction Vaccine‐induced thrombotic thrombocytopenia (VITT) has been reported after vaccination with the adenoviral vector coronavirus disease 2019 (COVID‐19) vaccine ChAdOx1 nCoV‐19 in European countries. To date, two cases of VITT have been reported in Thais after COVID‐19 vaccination...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Phichchapha Noikongdee, Pornnapa Police, Tichayapa Phojanasenee, Pichika Chantrathammachart, Pimjai Niparuck, Teeraya Puavilai, Angsana Phuphuakrat, Pantep Angchaisuksiri, Kochawan Boonyawat
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	COVID‐19 vaccines Platelet factor 4 Prevalence Thailand Vaccines Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/f89a226e458a4040a56b0044f65ecd60
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f89a226e458a4040a56b0044f65ecd60
record_format	dspace
spelling	oai:doaj.org-article:f89a226e458a4040a56b0044f65ecd602021-11-29T09:35:28ZPrevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais2475-037910.1002/rth2.12600https://doaj.org/article/f89a226e458a4040a56b0044f65ecd602021-10-01T00:00:00Zhttps://doi.org/10.1002/rth2.12600https://doaj.org/toc/2475-0379Abstract Introduction Vaccine‐induced thrombotic thrombocytopenia (VITT) has been reported after vaccination with the adenoviral vector coronavirus disease 2019 (COVID‐19) vaccine ChAdOx1 nCoV‐19 in European countries. To date, two cases of VITT have been reported in Thais after COVID‐19 vaccination. We determined the frequency of anti–platelet factor 4 (PF4)/polyanionic antibodies in the Thai population receiving the COVID‐19 vaccines. Methods We conducted a cross‐sectional study to evaluate the prevalence of anti‐PF4/polyanionic antibodies in health care workers who received COVID‐19 vaccination with ChAdOx1 nCoV‐19 or CoronaVac within 7 to 35 days. A control population who had not been vaccinated was also included. Anti‐PF4/polyanionic antibodies were detected using ELISA. Functional assay with platelet aggregation was performed for all positive anti‐PF4/polyanionic antibody ELISA tests. Results A total of 646 participants were included in the study; 221 received ChAdOx1 nCoV‐19, 232 received CoronaVac, and 193 participants were in the control group. The prevalence of anti‐PF4 antibodies was 2.3% (95% confidence interval [CI], 0.7‐5.2), 1.7% (95% CI, 0.5‐4.4) in the ChAdOx1 nCoV‐19 and CoronaVac groups, respectively. There was no positive test in the control group. None of the PF4/polyanionic positive sera induced platelet aggregation. Conclusion We found a low prevalence of anti‐PF4 antibodies in Thais after vaccination with ChAdOx1 nCoV‐19 and CoronaVac. None of the antibodies were functional and lacked an association with VITT.Phichchapha NoikongdeePornnapa PoliceTichayapa PhojanaseneePichika ChantrathammachartPimjai NiparuckTeeraya PuavilaiAngsana PhuphuakratPantep AngchaisuksiriKochawan BoonyawatWileyarticleCOVID‐19 vaccinesPlatelet factor 4PrevalenceThailandVaccinesDiseases of the blood and blood-forming organsRC633-647.5ENResearch and Practice in Thrombosis and Haemostasis, Vol 5, Iss 7, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID‐19 vaccines Platelet factor 4 Prevalence Thailand Vaccines Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	COVID‐19 vaccines Platelet factor 4 Prevalence Thailand Vaccines Diseases of the blood and blood-forming organs RC633-647.5 Phichchapha Noikongdee Pornnapa Police Tichayapa Phojanasenee Pichika Chantrathammachart Pimjai Niparuck Teeraya Puavilai Angsana Phuphuakrat Pantep Angchaisuksiri Kochawan Boonyawat Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais
description	Abstract Introduction Vaccine‐induced thrombotic thrombocytopenia (VITT) has been reported after vaccination with the adenoviral vector coronavirus disease 2019 (COVID‐19) vaccine ChAdOx1 nCoV‐19 in European countries. To date, two cases of VITT have been reported in Thais after COVID‐19 vaccination. We determined the frequency of anti–platelet factor 4 (PF4)/polyanionic antibodies in the Thai population receiving the COVID‐19 vaccines. Methods We conducted a cross‐sectional study to evaluate the prevalence of anti‐PF4/polyanionic antibodies in health care workers who received COVID‐19 vaccination with ChAdOx1 nCoV‐19 or CoronaVac within 7 to 35 days. A control population who had not been vaccinated was also included. Anti‐PF4/polyanionic antibodies were detected using ELISA. Functional assay with platelet aggregation was performed for all positive anti‐PF4/polyanionic antibody ELISA tests. Results A total of 646 participants were included in the study; 221 received ChAdOx1 nCoV‐19, 232 received CoronaVac, and 193 participants were in the control group. The prevalence of anti‐PF4 antibodies was 2.3% (95% confidence interval [CI], 0.7‐5.2), 1.7% (95% CI, 0.5‐4.4) in the ChAdOx1 nCoV‐19 and CoronaVac groups, respectively. There was no positive test in the control group. None of the PF4/polyanionic positive sera induced platelet aggregation. Conclusion We found a low prevalence of anti‐PF4 antibodies in Thais after vaccination with ChAdOx1 nCoV‐19 and CoronaVac. None of the antibodies were functional and lacked an association with VITT.
format	article
author	Phichchapha Noikongdee Pornnapa Police Tichayapa Phojanasenee Pichika Chantrathammachart Pimjai Niparuck Teeraya Puavilai Angsana Phuphuakrat Pantep Angchaisuksiri Kochawan Boonyawat
author_facet	Phichchapha Noikongdee Pornnapa Police Tichayapa Phojanasenee Pichika Chantrathammachart Pimjai Niparuck Teeraya Puavilai Angsana Phuphuakrat Pantep Angchaisuksiri Kochawan Boonyawat
author_sort	Phichchapha Noikongdee
title	Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais
title_short	Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais
title_full	Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais
title_fullStr	Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais
title_full_unstemmed	Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais
title_sort	prevalence of anti–platelet factor 4/polyanionic antibodies after covid‐19 vaccination with chadox1 ncov‐19 and coronavac in thais
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/f89a226e458a4040a56b0044f65ecd60
work_keys_str_mv	AT phichchaphanoikongdee prevalenceofantiplateletfactor4polyanionicantibodiesaftercovid19vaccinationwithchadox1ncov19andcoronavacinthais AT pornnapapolice prevalenceofantiplateletfactor4polyanionicantibodiesaftercovid19vaccinationwithchadox1ncov19andcoronavacinthais AT tichayapaphojanasenee prevalenceofantiplateletfactor4polyanionicantibodiesaftercovid19vaccinationwithchadox1ncov19andcoronavacinthais AT pichikachantrathammachart prevalenceofantiplateletfactor4polyanionicantibodiesaftercovid19vaccinationwithchadox1ncov19andcoronavacinthais AT pimjainiparuck prevalenceofantiplateletfactor4polyanionicantibodiesaftercovid19vaccinationwithchadox1ncov19andcoronavacinthais AT teerayapuavilai prevalenceofantiplateletfactor4polyanionicantibodiesaftercovid19vaccinationwithchadox1ncov19andcoronavacinthais AT angsanaphuphuakrat prevalenceofantiplateletfactor4polyanionicantibodiesaftercovid19vaccinationwithchadox1ncov19andcoronavacinthais AT pantepangchaisuksiri prevalenceofantiplateletfactor4polyanionicantibodiesaftercovid19vaccinationwithchadox1ncov19andcoronavacinthais AT kochawanboonyawat prevalenceofantiplateletfactor4polyanionicantibodiesaftercovid19vaccinationwithchadox1ncov19andcoronavacinthais
_version_	1718407441678336000

Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais

Ejemplares similares